Genetic Differences in Lung Cancer: EGFR vs KRAS Mutations
Author Information
Author(s): Blons Hélène, Pallier Karine, Le Corre Delphine, Danel Claire, Tremblay-Gravel Maxime, Houdayer Claude, Fabre-Guillevin Elizabeth, Riquet Marc, Dessen Philippe, Laurent-Puig Pierre
Primary Institution: UMR-S775, INSERM, Paris, France
Hypothesis
What are the molecular alterations associated with EGFR mutations in lung cancer?
Conclusion
The study found distinct genetic alteration patterns between EGFR and KRAS mutated lung adenocarcinomas.
Supporting Evidence
- Patterns of alterations were different between EGFR and KRAS mutated tumors.
- Specific chromosome alterations were linked to the EGFR mutated group.
- Homozygous deletions at CDKN2A were linked to EGFR mutations and absence of smoking.
- Cyclin amplifications were associated with TP53 mutations and smoking habit.
Takeaway
This study looked at how different genes change in lung cancer based on whether the cancer has EGFR or KRAS mutations, finding that they behave differently.
Methodology
The study used genome wide SNP Array analysis to compare genetic profiles of EGFR and KRAS mutated adenocarcinomas.
Limitations
The study focused on a limited series of tumors.
Participant Demographics
All tumors selected were from women.
Statistical Information
P-Value
p = 0.027, p = 0.032, p = 0.042, p = 0.043
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website